• 掃描立即下載
    掃描立即下載

UTHR 聯合治療

471.99
3.74
(-0.79%)

聯合治療 UTHR 生物技術：藥物製劑

471.99
3.74
(-0.79%)
showMore
單位：美金千元
科目 2025/Q3 2025/Q2 2025/Q1 2024/Q4 2024/Q3 2024/Q2 2024/Q1 2023/Q4 2023/Q3 2023/Q2 2023/Q1 2022/Q4 2022/Q3 2022/Q2 2022/Q1 2021/Q4 2021/Q3 2021/Q2 2021/Q1 2020/Q4
營業收入淨額
799,500 798,600 794,400 735,900 748,900 714,900 677,700 614,700 609,400 596,500 506,900 491,500 516,000 466,900 461,900 415,200 444,700 446,500 379,100 384,900
營業成本
100,900 87,600 92,500 75,900 83,100 77,800 72,900 71,000 70,100 64,100 52,300 58,800 37,200 29,700 25,900 34,600 27,700 37,200 23,000 34,800
營業毛利
698,600 711,000 701,900 660,000 665,800 637,100 604,800 543,700 539,300 532,400 454,600 432,700 478,800 437,200 436,000 380,600 417,000 409,300 356,100 350,100
營業費用
309,300 324,800 - - - - 248,500 283,600 212,300 219,000 170,200 257,100 164,500 235,400 148,000 210,800 188,300 187,100 420,900 284,800
研發費用
127,500 134,000 149,000 133,800 103,500 139,600 104,100 151,400 84,700 89,000 82,900 93,900 66,100 93,900 69,000 82,900 79,200 74,300 303,700 126,100
推銷及管理費用
181,800 190,800 170,100 168,500 219,200 177,600 144,400 132,200 127,600 130,000 87,300 163,200 98,400 141,500 79,000 127,900 109,100 112,800 117,200 158,700
非經常性項目費用
- - - - - - - - - - - - - - - - - - - -
其他營業費用
- - - - - - - - - - - - - - - - - - - -
營業利益
389,300 386,200 382,800 357,700 343,100 319,900 356,300 260,100 327,000 313,400 284,400 175,600 314,300 201,800 288,000 169,800 228,700 222,200 -64,800 65,300
其他收入及費用
- - 46,800 46,700 55,600 47,000 55,600 50,400 40,400 36,600 21,300 15,500 7,400 -45,000 25,400 -24,600 -19,700 -1,000 101,900 53,900
利息費用
3,000 7,300 6,100 7,900 10,100 11,600 13,300 15,100 15,600 14,800 13,800 12,300 9,200 6,200 4,700 4,700 4,600 4,700 4,600 4,800
稅前純益
438,000 408,400 423,500 396,500 388,600 355,300 398,600 295,400 351,800 335,200 291,900 178,800 312,500 150,600 308,700 140,500 204,400 216,500 32,500 114,400
所得稅
99,300 98,900 101,300 95,200 79,500 77,200 92,000 78,300 84,200 76,000 51,000 46,700 73,200 34,600 68,800 28,300 41,700 43,900 4,200 15,600
稅後純益
338,700 309,500 322,200 301,300 309,100 278,100 306,600 217,100 267,600 259,200 240,900 132,100 239,300 116,000 239,900 112,200 162,700 172,600 28,300 98,800
基本每股稅後盈餘(元)
7.73 6.86 7.18 6.74 6.93 6.26 6.52 4.62 5.71 5.53 5.2 2.88 5.26 2.56 5.31 2.49 3.62 3.85 0.63 2.22
稀釋每股稅後盈餘(元)
7.15 6.39 6.63 6.21 6.4 5.86 6.17 4.33 5.4 5.22 4.86 2.65 4.92 2.4 5.03 2.34 3.44 3.67 0.61 2.17
基本平均股數(千股)
43,800 45,100 44,900 44,700 44,600 44,400 47,000 47,000 46,900 46,900 46,300 45,800 45,500 45,400 45,200 45,100 44,900 44,800 44,600 44,500
稀釋平均股數(千股)
47,300 48,300 48,600 48,700 48,400 47,500 49,700 49,800 49,700 49,500 49,600 49,400 48,700 48,100 47,700 47,800 47,600 47,300 46,400 45,100
還原基本每股稅後盈餘(元)
7.73 6.86 7.18 6.74 6.93 6.26 6.52 4.62 5.71 5.53 5.2 2.88 5.26 2.56 5.31 2.49 3.62 3.85 0.63 2.22
還原稀釋每股稅後盈餘(元)
7.15 6.39 6.63 6.21 6.4 5.86 6.17 4.33 5.4 5.22 4.86 2.65 4.92 2.4 5.03 2.34 3.44 3.67 0.61 2.17
還原基本平均股數(千股)
43,800 45,100 44,900 44,700 44,600 44,400 47,000 47,000 46,900 46,900 46,300 45,800 45,500 45,400 45,200 45,100 44,900 44,800 44,600 44,500
還原稀釋平均股數(千股)
47,300 48,300 48,600 48,700 48,400 47,500 49,700 49,800 49,700 49,500 49,600 49,400 48,700 48,100 47,700 47,800 47,600 47,300 46,400 45,100
EBITDA(千元)
462,900 436,800 449,400 424,100 417,800 385,600 426,900 324,200 380,700 362,900 319,000 204,300 334,600 169,500 325,900 157,800 221,400 233,600 49,600 132,300

目前沒有任何討論